设为首页 加入收藏

TOP

Zaltra(ziv-aflibercept)(八)
2013-06-18 15:02:09 来源: 作者: 【 】 浏览:9038次 评论:0
ect of renal impairment on the pharmacokinetics of ziv-aflibercept.

Based on a population PK analysis with data from 1507 patients, ziv-aflibercept exposure in patients with mild, moderate, and severe renal impairment were similar to those in patients with normal renal function [see Clinical Pharmacology (12.3)].

Females and Males of Reproductive Potential
Male and female reproductive function and fertility may be compromised during treatment with Zaltrap, as suggested by findings in monkeys [see Nonclinical Toxicology (13.1)]. These animal findings were reversible within 18 weeks after cessation of treatment. Females and males of reproductive potential should use highly effective contraception during and up to a minimum of 3 months after the last dose of treatment.

Overdosage
There have been no cases of overdose reported with Zaltrap. There is no information on the safety of Zaltrap given at doses exceeding 7 mg per kg every 2 weeks or 9 mg per kg every 3 weeks.

Zaltrap Description
Ziv-aflibercept is a recombinant fusion protein consisting of Vascular Endothelial Growth Factor (VEGF)-binding portions from the extracellular domains of human VEGF Receptors 1 and 2 fused to the Fc portion of the human IgG1. Ziv-aflibercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) K-1 mammalian expression system. Ziv-aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa.

Zaltrap is a sterile, clear, colorless to pale yellow, non-pyrogenic, preservative-free, solution for administration by intravenous infusion. Zaltrap is supplied in single-use vials of 100 mg per 4 ml and 200 mg per 8 ml formulated as 25 mg/mL ziv-aflibercept in polysorbate 20 (0.1%), sodium chloride (100 mM), sodium citrate (5 mM), sodium phosphate (5 mM), and sucrose (20%), in Water for Injection USP, at a pH of 6.2.

Zaltrap - Clinical Pharmacology
Mechanism of Action
Ziv-aflibercept acts as a soluble receptor that binds to human VEGF-A (equilibrium dissociation constant KD of 0.5 pM for VEGF-A165 and 0.36 pM for VEGF-A121), to human VEGF-B (KD of 1.92 pM), and to human PlGF (KD of 39 pM for PlGF-2). By binding to these endogenous ligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. This inhibition can result in decreased neovascularization and decreased vascular permeability.

In animals, ziv-aflibercept was shown to inhibit the proliferation of endothelial cells, thereby inhibiting the growth of new blood vessels. Ziv-aflibercept inhibited the growth of xenotransplanted colon tumors in mice.

Pharmacokinetics
Plasma concentrations of free and VEGF-bound ziv-aflibercept were measured using specific enzyme-linked immunosorbent assays (ELISAs). Free ziv-aflibercept concentrations appear to exhibit linear pharmacokinetics in the dose range of 2–9 mg/kg. Following 4 mg/kg every two weeks intravenous administration of Zaltrap, the elimination half-life of free ziv-aflibercept was approximately 6 days (range 4–7 days). Steady state concentrations of free ziv-aflibercept were reached by the second dose. The accumulation ratio for free ziv-aflibercept was approximately 1.2 after administration of 4 mg/kg every two weeks.

Specific Populations

Based on a population pharmacokineti

以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 5 6 7 8 9 10 11 下一页 尾页 8/11/11
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇BLENOXANE(bleomycin sulfate fo.. 下一篇KADCYLA (trastuzumab emtansine)..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位